SBIR/STTR Research Award

MEASURING CYTOGENETIC DAMAGE IN HUMAN BLOOD

Award identifier 4b52644e237cb858de435e905c285cf040f105d9641f0e16115e3643ca994ae0Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$0

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Litron Laboratories Ltd
Proposal award date
Not reported
Contract end date
Not reported
UEI
LJH7LE9AUHL5
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Humans are exposed to genotoxic agents through a variety of sources. Micronucleus (MN) formation is an endpoint which can be used to detect DNA damage resulting from clastogenic or aneugenic mechanisms. A sensitive and high throughput system to measure human blood for MN would have a myriad of biomonitoring applications. For example, such a system could provide information regarding the chromosome damaging activity of new drugs undergoing clinical trials, chemotherapy regimens, as well as accidental radiation or chemical exposures. A goal of the current application is to optimize methods developed during Phase 1 that allow for the flow cytometric measurement of MN in human reticulocytes (RETs0. Experiments are planned to test whether MN-RET measurements represent a sensitive indicator of cytogenetic damage. To achieve this goal, our Phase II aims are to. 1. COMPLETE optimization of cell staining and handling procedures. 2. DEVELOP biological standards to aid the calibration of flow cytometer parameters. 3. MEASURE the time-course and magnitude of MN-RET induction in radiotherapy and radio-plus chemo-therapy patients before and during the course of treatment. 4. MEASURE the time-course and magnitude of MN-RET induction in radiotherapy and radio-plus chemo-therapy patients before and during the course of treatment. 5. COLLABORATE with researchers in an environmental biomonitoring study of Chernobyl liquidators, clean-up workers and settlers. PROPOSED COMMERCIAL APPLICATIONS: The successful completion of this research project will enable Litron Laboratories to become an expert facility, capable of performing cytogenetic measurements on human blood samples on a fee-for-fee service basis. Additionally, by developing the necessary reagents into kit format, it will be possible to make this technology available to other laboratories having access to a single-laser flow cytometer. This technologically innovative technique has the potential to become an important clinical tool for measuring DNA damage carried by environmental exposures: radiation and/or chemotherapeutic therapies, aging and a myriad of other possible sources.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

42 SBIR/STTR records share this UEI (1985–2025). Reported award amounts total $18,400,554. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.